Literature DB >> 21191725

Effects of timolol-related ophthalmic solutions on cultured human conjunctival cells.

Kazuhide Kawase1, Wenzhong Lin, Yumiko Aoyama, Tetsuya Yamamoto, Masamitsu Shimazawa, Hideaki Hara.   

Abstract

PURPOSE: To investigate the inhibitory effects of drugs containing timolol on the proliferation of human conjunctival cells in vitro.
METHODS: Timoptol, Timoptol XE, Rysmon TG, and Timabak solutions were used. These commercially available drugs were diluted to 1/30, 1/100, and 1/300, and their effects on cell morphology, cell count, and cell activity were investigated. The effects of drugs containing benzalkonium chloride (BAK) as well as those of the Rysmon TG vehicle alone were also assessed.
RESULTS: At 1/30 dilution, cells treated with Timoptol and Timoptol XE showed cell deformation. Timoptol and Timoptol XE also caused a significant decrease in the number of cells at 1/100 and 1/30 dilutions. Cell activity decreased in a concentration-dependent manner after the addition of either Timoptol or Timoptol XE. Rysmon TG and Timabak showed significantly higher cell activity than Timoptol or Timoptol XE at both 1/100 and 1/30 dilutions. The cell count increased in a concentration-dependent manner in the BAK-free group, while cell activity decreased in a concentration-dependent manner in the cultures in the BAK-containing group.
CONCLUSIONS: Compared with Timoptol and Timoptol XE, Rysmon TG and Timabak showed milder toxicity on human conjunctival cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191725     DOI: 10.1007/s10384-010-0881-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  31 in total

1.  Basal tear turnover and topical timolol in glaucoma patients and healthy controls by fluorophotometry.

Authors:  E V Kuppens; T R Stolwijk; R J de Keizer; J A van Best
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-11       Impact factor: 4.799

2.  [Conjunctival changes related to topical treatment and effectiveness of surgery in glaucoma].

Authors:  C Stefan; A Nenciu; Mihaela Balas; Alina Neacşu; Luminiţa Dachin; Carmen Ardelean
Journal:  Oftalmologia       Date:  2003

Review 3.  Drug-induced pemphigoid. A spectrum of diseases.

Authors:  P M Fiore; I H Jacobs; D B Goldberg
Journal:  Arch Ophthalmol       Date:  1987-12

4.  Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells.

Authors:  C Debbasch; P J Pisella; M De Saint Jean; P Rat; J M Warnet; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-10       Impact factor: 4.799

5.  Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.

Authors:  M De Saint Jean; F Brignole; A F Bringuier; A Bauchet; G Feldmann; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

6.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

7.  Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells.

Authors:  Seth P Epstein; Dongmei Chen; Penny A Asbell
Journal:  J Ocul Pharmacol Ther       Date:  2009-10       Impact factor: 2.671

8.  Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications.

Authors:  I R Schwab; J V Linberg; V M Gioia; W H Benson; G M Chao
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

9.  Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.

Authors:  D C Broadway; I Grierson; C O'Brien; R A Hitchings
Journal:  Arch Ophthalmol       Date:  1994-11

10.  Glaucoma in patients with ocular cicatricial pemphigoid.

Authors:  J Tauber; S Melamed; C S Foster
Journal:  Ophthalmology       Date:  1989-01       Impact factor: 12.079

View more
  3 in total

1.  Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?

Authors:  D Lockington; E C A Macdonald; P Stewart; D Young; M Caslake; K Ramaesh
Journal:  Eye (Lond)       Date:  2012-03-02       Impact factor: 3.775

Review 2.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30

3.  An in situ Gelling System Based on Methylcellulose and Tranilast Solid Nanoparticles Enhances Ocular Residence Time and Drug Absorption Into the Cornea and Conjunctiva.

Authors:  Noriaki Nagai; Misa Minami; Saori Deguchi; Hiroko Otake; Hiroshi Sasaki; Naoki Yamamoto
Journal:  Front Bioeng Biotechnol       Date:  2020-07-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.